ArticleStroke2026
Mapping the mRS Into the EQ-5D-5L in Patients With Ischemic Stroke.
Article in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mapping the Problem Areas in Diabetes (PAID) and Diabetes Distress Scale (DDS) to the EQ-5D-5L in diabetes care.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMapping concerns the cross-walking of one health-related quality of life instrument to another. This study aimed to translate the modified Rankin Scale (mRS) score at 3 months after ischemic stroke into 5-level version of the EQ-5D (EQ-5D-5L)-based utility values, which may be used for the derivation of quality-adjusted life years for cost-effectiveness analyses.
methodsData from 3 Dutch multicenter phase III clinical trials in ischemic stroke were pooled (MR CLEAN [Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands]-NO-IV, MR CLEAN-MED, and MR CLEAN-LATE). The mRS and EQ-5D-5L were assessed by telephone interview at 3 months poststroke. The correlation (Spearman coefficient) between the mRS and each EQ-5D-5L domain was assessed. Various direct and indirect mapping algorithms were explored. Model performance (predictive ability) was assessed using bootstrapping in the full testing set (mRS score 0-5) and in patients with independent (0-2) and dependent (3-5) mRS scores separately. Results were validated in an external validation set derived from a cross-sectional Dutch study. Final utility estimates per mRS score were assessed in the pooled trial and external validation data set.
resultsThe EQ-5D-5L dimensions self-care, daily activities, and mobility demonstrated the strongest correlation to the mRS (
conclusionsThe mean utility weights provided in this study may be used for the direct estimation of quality-adjusted life years from mRS scores. Furthermore, the multinomial logit model may be used to derive utility values from new data sets with different country-specific utility tariffs. Our results are ideally suited for application in cost-effectiveness analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.